

<https://helda.helsinki.fi>

Toxicological characterisation of two novel selective aryl hydrocarbon receptor modulators in Sprague-Dawley rats

Mahiout, Selma

2017-07-01

Mahiout , S , Linden , J , Esteban , J , Sanchez-Perez , I , Sankari , S , Pettersson , L , Håkansson , H & Pohjanvirta , R 2017 , ' Toxicological characterisation of two novel selective aryl hydrocarbon receptor modulators in Sprague-Dawley rats ' , Toxicology and Applied Pharmacology , vol. 326 , pp. 54-65 . <https://doi.org/10.1016/j.taap.2017.04.020>

<http://hdl.handle.net/10138/234476>

<https://doi.org/10.1016/j.taap.2017.04.020>

cc_by_nc_nd

acceptedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Toxicological characterisation of two novel selective aryl hydrocarbon receptor modulators in Sprague-Dawley rats

Selma Mahiout^a, Jere Lindén^b, Javier Esteban^c, Ismael Sánchez-Pérez^c, Satu Sankari^d, Lars Pettersson^e, Helen Håkansson^f and Raimo Pohjanvirta^a

^a Department of Food Hygiene and Environmental Health, Faculty of Veterinary Medicine, University of Helsinki, Finland

^b Department of Basic Veterinary Sciences, Faculty of Veterinary Medicine, University of Helsinki, Finland

^c Instituto de Bioingeniería, Universidad Miguel Hernández de Elche, Elche, Alicante, Spain

^d Central Laboratory of the Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, Finland

^e Immunahr AB, Lund, Sweden

^f Institute of Environmental Medicine (IMM), Karolinska Institutet, Stockholm, Sweden

Corresponding author: Selma Mahiout

Dept. of Food Hygiene and Environmental Health, Faculty of Veterinary Medicine

Mustialankatu 1, FI-00790 Helsinki, Finland

Email: selma.mahiout@helsinki.fi

Phone: 00358-2941-57427

Fax: 00358-2941-57161

Preliminary results of some of the data were presented at 50th Congress of the European Societies of Toxicology (Eurotox 2014), 7-10 September 2014, Edinburgh, Scotland, UK; Society of Toxicology's 55th Annual Meeting, 13-17 March 2016, New Orleans, LA, USA (SOT 2016) and AHR Conference 2016: The Aryl Hydrocarbon Receptor as a Central Mediator of Health and Disease, 3-6 August 2016, Rochester, NY, USA.

Abstract

The aryl hydrocarbon receptor (AHR) mediates the toxicity of dioxins, but also plays important physiological roles. Selective AHR modulators, which elicit some effects imparted by this receptor without causing the marked toxicity of dioxins, are presently under intense scrutiny. Two novel such compounds are IMA-08401 (*N*-acetyl-*N*-phenyl-4-acetoxy-5-chloro-1,2-dihydro-1-methyl-2-oxo-quinoline-3-carboxamide) and IMA-07101 (*N*-acetyl-*N*-(4-trifluoromethylphenyl)-4-acetoxy-1,2-dihydro-5-methoxy-1-methyl-2-oxo-quinoline-3-carboxamide). They represent, as diacetyl prodrugs, AHR-active metabolites of the drug compounds laquinimod and tasquinimod, respectively, which are intended for the treatment of autoimmune diseases and cancer. Here, we toxicologically assessed the novel compounds in Sprague-Dawley rats, after a single dose (8.75–92.5 mg/kg) and 5-day repeated dosing at the highest doses achievable (IMA-08401: 100 mg/kg/day; and IMA-07101: 75 mg/kg/day). There were no overt clinical signs of toxicity, but body weight gain was marginally retarded, and the treatments induced minimal hepatic extramedullary haematopoiesis. Further, both the absolute and relative weights of the thymus were significantly decreased. *Cyp1a1* gene expression was substantially increased in all tissues examined. The hepatic induction profile of other AHR battery genes was distinct from that caused by TCDD. The only marked alterations in serum clinical chemistry variables were a reduction in triglycerides and an increase in 3-hydroxybutyrate. Liver and kidney retinol and retinyl palmitate concentrations were affected largely in the same manner as reported for TCDD. *In vitro*, the novel compounds activated CYP1A1 effectively in H4IIE cells. Altogether, these novel compounds appear to act as potent activators of the AHR, but lack some major characteristic toxicities of dioxins. They therefore represent promising new selective AHR modulators.

Keywords: AH-receptor; selective modulators; IMA-08401; IMA-07101; TCDD; toxicity

1. Introduction

The aryl hydrocarbon receptor (AHR) is an evolutionarily ancient, ligand-activated transcription factor (Beischlag, et al. 2008). It regulates the activity of various genes in different cell types across all vertebrates, and is well known and extensively studied as the mediator of toxicity induced by a class of environmental contaminants called dioxins [polychlorinated dibenzo-para-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and dioxin-like polychlorinated biphenyls (PCBs); reviewed, for example, in (Hahn and Karchner 2011, Mandal 2005)]. More recently, evidence about the importance of the AHR in numerous physiological phenomena has started to emerge, thus revealing its potential as a target for novel pharmacological therapies in several fields. Known endogenous functions of the AHR so far include, for instance, participation in the metabolism of xenobiotics; regulation of reproduction, development, cell growth and differentiation; and modulation of autoimmunity [reviewed for example in (Esser, et al. 2009, Fujii-Kuriyama and Kawajiri 2010, McMillan and Bradfield 2007)]. Furthermore, recent studies have revealed a role for the AHR in the control of intestinal microbiota and innate immunity (Kiss, et al. 2011, Lee, et al. 2012, Moura-Alves, et al. 2014).

The molecular mechanism of AHR action has been revealed in detail for transcriptional induction of a drug-metabolising enzyme, CYP1A1, which is believed to represent a more general pattern, known as the canonical pathway of AHR signalling. In its inactive state, the AHR is located in the cytosol in association with the chaperone proteins HSP90, XAP2 and p23. Binding of a ligand such as 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) triggers transformation in the protein structure causing the AHR to translocate into the nucleus. There it sheds the cytosolic protein partners and dimerizes with a structurally related protein, ARNT. The AHR-ARNT dimer then binds to the DNA at specific enhancer sites called dioxin response elements (DREs) in the promoter region of the *Cyp1a1* gene, eventually leading to induced transcription of CYP1A1 mRNA (Ma 2011). This is a fairly rapid and highly sensitive marker for AHR activation (Abraham, et al. 1988). CYP1A1 activity *in vivo* can result in metabolic activation of potentially genotoxic compounds such as polycyclic aromatic hydrocarbons (Shimada and

Fujii-Kuriyama 2004), but the predominant consequence of its enhanced activity seems to be protective due to augmented detoxification capacity (Nebert, et al. 2004). Additional consequences of elevated CYP1A1 activity include changes in the metabolism of a variety of endogenous molecules with signalling properties, e.g. retinoids (Lampen, et al. 2000, Shmarakov 2015), steroid hormones (Spink, et al. 1992) and, apparently, polyunsaturated fatty acids (Hankinson 2016). Further, unlike previously presumed, *Cyp1a1* induction does not automatically indicate dioxin-like toxicity (Hu, et al. 2007, Pohjanvirta, et al. 2011).

TCDD is the most toxic dioxin and has, as such, been widely employed in research as a classical compound for activation of the AHR (Van Den Berg, et al. 1998). As dioxins in general, it is chemically highly persistent and hydrophobic, which leads to its accumulation in the food chain (Travis and Hattemer-Frey 1991). TCDD causes a multitude of adverse effects in laboratory animals including hypophagia, wasting syndrome, developmental toxicity, endocrine disruption, carcinogenicity and immunotoxicity (Pohjanvirta and Tuomisto 1994). The current consensus is that these ultimately result from inappropriate and untimely activation of the AHR (Bock and Köhle 2006, Denison, et al. 2011). However, some of the biological impacts of TCDD are such that they could be potentially beneficial in the treatment of certain diseases, if they could be separated from the toxicity. These impacts are particularly related to immunomodulation (Zhu, et al. 2014). Appropriate activation of AHR, devoid of TCDD-like toxicity, could thus lead to novel therapeutics for treatment of, for instance, cancer, multiple sclerosis (MS), inflammatory skin diseases, Crohn's disease and colitis (Arsenescu, et al. 2011, Benson and Shepherd 2011, Díaz-Díaz, et al. 2016, Furumatsu, et al. 2011, Haas, et al. 2016, Jin, et al. 2014, Quintana, et al. 2008, Van Den Bogaard, et al. 2013).

Selective AHR modulators, which elicit some desired effects imparted by AHR without causing the marked toxicity of dioxins, are presently under intense scrutiny (Safe, et al. 2013). This is in part due to their potential as novel pharmacological compounds, but also because they could be useful tools in

the quest of further elucidating the molecular mechanisms at play in the biological and toxicological roles of the AHR. Two recently introduced such molecules are IMA-08401 (later referred to as C2; Fig. 2) and IMA-07101 (later C4). They represent novel diacetyl prodrugs of AHR-active *N*-hydrogen metabolites of the immunomodulatory drug compounds laquinimod and tasquinimod, which are intended for treatment of MS and prostate cancer, respectively (Isaacs, et al. 2006, Polman, et al. 2005). *In vivo*, the prodrugs C2 and C4 readily hydrolyse to provide the deacetylated active compounds IMA-06201 (C1) and IMA-06504 (C3; unpublished data). The chemical relationships between the prodrug C2, laquinimod and the AHR-active form C1 are depicted in Fig. 1. C1 and C3 have previously been shown to be effective AHR activators *in vitro* [(Pettersson 2012) and unpublished data], but they are unsuitable for *in vivo* formulations due to their low aqueous solubility. Therefore, little information exists on the activity and toxicity of these compounds *in vivo* thus far. Here, the short-term toxicity of C2 and C4 was assessed in Sprague-Dawley (S-D) rats and compared with properties earlier established in the literature for TCDD. Both acute (single exposure) and subacute (daily dosing on five consecutive days) toxicities were studied. In addition, the AHR activation potential of the active compounds C1 and C3 relative to TCDD was screened *in vitro* by measuring CYP1A1 enzyme activity in the rat hepatoma cell line H4IIE.

----- **Fig. 1 approximately here** -----

2. Materials and Methods

2.1. Chemicals

The test compounds C1 (IMA-06201; *N*-ethyl-*N*-phenyl-5-chloro-1,2-dihydro-4-hydroxy-1-methyl-2-oxo-quinoline-3-carboxamide;; CAS Registry Number: 879410-94-3; Fig. 2), C2 (IMA-08401; *N*-acetyl-*N*-phenyl-4-acetoxy-5-chloro-1,2-dihydro-1-methyl-2-oxo-quinoline-3-carboxamide; CAS: 1373260-17-3), C3 (IMA-06504; *N*-(4-trifluoromethylphenyl)-1,2-dihydro-4-hydroxy-5-methoxy-1-methyl-2-oxo-quinoline-3-carboxamide; CAS: 1373259-57-4) and C4 (IMA-07101; *N*-acetyl-*N*-(4-trifluoromethylphenyl)-4-acetoxy-1,2-dihydro-5-methoxy-1-methyl-2-oxo-quinoline-3-carboxamide; CAS: 1373259-76-7) were synthesized as described by Pettersson (2012). C2 and C4 stock solutions for the *in vivo* studies were prepared by mixing the compounds with PEG-400 (Ph. Eur. grade, Sigma-Aldrich, St. Louis, MO, USA) and heating them in +80°C water bath for 1 h, with intermittent vortexing. Dilutions were prepared from the stocks with PEG-400. For *in vitro* study stock solutions, C1, C3 and TCDD were dissolved in DMSO (Sigma-Aldrich). C3 in DMSO was heated in +65°C water bath for 45 min to dissolve. TCDD was purchased from Ufa-Institute (Ufa, Russia) and was over 98% pure as assessed by gas chromatography–mass spectrometry. The stock solutions were further diluted with cell culture medium before application to cells.

----- Fig. 2 approximately here -----

2.2. Animals and their husbandry

S-D rats (males, ~9 weeks of age at exposures) were purchased from Harlan Netherlands. The rats were acclimatised to study conditions and handling for a minimum of one week after arrival, and were housed in groups of two or three in individually ventilated cages (Sealsafe IVC Blue Line, Techniplast, West Chester, PA, USA) throughout the studies. The rats were maintained on a 12-h light/dark cycle. The lights came on at 6 a.m., and during the night the room was lit with a dim red light. The cage floor

was covered with aspen wood bedding (Tapvei, Estonia), and each cage enriched with a transparent red plastic hiding tube, nesting material and chew blocks (both aspen wood, Tapvei, Estonia). Commercial pelleted rat chow [RM1 (E) SQC Expanded; SDS Diets, Witham, Essex, England; 8554.27 International units vitamin A/kg diet] and filtered, UV-irradiated tap water were available *ad libitum*. The animal room was air-conditioned, the temperature kept at $22 \pm 1^\circ\text{C}$ and relative humidity at 38–75% (typically 50%).

All studies were authorized by the National Animal Experiment Board in Finland (Eläinkoelautakunta, ELLA; project licence code: ESAVI/6882/04.10.03/2012). All procedures were conducted in accordance with the Directive 2010/63/EU of the European Parliament and of the Council.

2.3. Experimental design

Within the experiments, rats were randomly allocated into groups, which were matched for body weight (BW). In both experiments, the rats were weighed immediately before exposures and dosed intragastrically by oral gavage according to BW. The compounds were administered after a 3-h fast, for which rats were moved into identical but clean cages, where only water was available for the duration of the fast. After exposures, the fast was further continued for 3 h. At the end of the studies, carbon dioxide was used for euthanasia.

An **acute toxicity study** was carried out as a pilot experiment to make sure that the novel compounds C2 and C4 would not cause marked acute toxicity before their repeated administration to larger groups of rats. The study principle was loosely based on the OECD test guideline for acute oral toxicity [Up-and-Down-Procedure (OECD 2008)] to reduce the number of animals required. Estimation of LD50 values proved impossible because of the low toxicity and poor solubility of the compounds (see Results). Three different dose levels were tested for both compounds, the high doses being limited by

the maximum solubility of the compounds achieved (~18.5 mg/ml for C2 and ~15 mg/ml for C4). For C2, the dose levels tested were 8.75 (n=1), 17.5 (n=1), 30 (n=2) and 92.5 mg/kg (n=3). For C4, the dose levels were 8.75 (n=2), 27.5 (n=2) and 75 mg/kg (n=3). In addition, there was a control group (n=6) that received the vehicle (PEG-400).

The single exposures were started by administering the low dose of 17.5 mg/kg of C2 to a single rat at a volume of 10 ml/kg (day 0). As at 24 h after the exposure the rat seemed otherwise healthy but its faeces were runny [a known possible side effect of PEG-400 (Hermansky, et al. 1995, Ueda, et al. 2011)], the volume administered for the rest of the rats was lowered to 5 ml/kg, which ameliorated the diarrhoea. Three days later (day 3), the exposures were continued with 8.75 mg/kg of C2 (n=1), 30 mg/kg of C2 (n=2), 8.75 mg/kg of C4 (n=2), and the vehicle for the control group (n=4). After 48 h (day 5), a further two control rats received the vehicle and rats of the experimental groups the test compounds as follows: 27.5 mg/kg C4 (n=2), 75 mg/kg C4 (n=3) and 92.5 mg/kg C2 (n=3). All rats were observed individually at least once during the first 30 min after dosing, and periodically thereafter during the first 24 h, with special attention given in the first 4 h. Each rat was also weighed and monitored daily for any clinical signs of toxicity, before being euthanised (on day 7–13 after exposure). After euthanasia, the thymus and liver were excised and weighed.

A **subacute toxicity study** explored the properties and toxicities of C2 and C4 after repeated administrations on five consecutive days. Five to six males were used per group. On the first day of exposures, the rats weighed 277 ± 12 g (n=17; mean \pm SD). The substances were dosed at the highest concentrations attainable (which had proven to be not acutely toxic in the pilot experiment): 100 mg/kg/day for C2 and 75 mg/kg/day for C4. The volume administered was 5 ml/kg. The control group was treated with the same volume of the vehicle (PEG-400). After dosing, the rats were observed individually at least once during the first 30 min and periodically thereafter during the first 24 h, with special attention given during the first 4 h. They were weighed daily starting from the first day of

exposure (day 0), and after the last exposure they were further monitored for five days (until day 9) for any clinical signs. The rats were fasted for 5–10 h prior to euthanasia, which started at ~12.30 p.m. and finished within 6 h (animals of the three groups were euthanised in a rotating order). The thymus, liver, kidneys, testes and spleen were weighed. Serum, liver, duodenum, kidney, lung and testis samples were frozen in liquid nitrogen for further processing, and in addition samples from liver, spleen, kidney, lung and both testes were collected for histopathology.

2.4. Histopathology

Histological samples from the subacute toxicity study (liver, spleen, kidney, lung and testis) were fixed in 4% buffered formalin, embedded in paraffin and sectioned at 4 µm thickness. Slides were stained with hematoxylin-eosin for histopathological analysis. Microscopic findings were classified with standard pathological nomenclature and the severities of findings were graded on a scale of 1 to 4 as minimal, mild, moderate or marked, respectively. The grades of severity for microscopic findings were subjective; minimal was the least extent discernible. Microscopic findings that are not usually graded were listed as present.

2.5. Clinical chemistry

Clinical chemistry analyses following the subacute study were carried out at the Central Laboratory of the Department of Equine and Small Animal Medicine Helsinki, Finland. Enzymatic methods were used for the determination of serum free fatty acids (FFA; a.k.a. long-chain fatty acids [LCFA] or non-esterified fatty acids [NEFA]) (NEFA-C, Waco Chemicals GmbH, Neuss, Germany) and D-3-hydroxybutyrate (3-HB; RANBUT, Randox Laboratories Ltd. Crumlin, UK). The analyses were performed with an automatic chemistry analyser (KONE Pro Selective Chemistry Analyser, Thermo Fisher Scientific, Vantaa, Finland).

The rest of the serum analytes were analysed using the reagents and adaptations recommended by the manufacturer of the automatic chemistry analyser (Konelab 30i, Thermo Fisher Scientific, Vantaa, Finland). The activities of alanine aminotransferase [ALAT; (Schumann, et al. 2002a)] and aspartate aminotransferase [ASAT; (Schumann, et al. 2002b)] were measured according to the reference method of International Federation of Clinical Chemistry and Laboratory Medicine (IFCC 2002/5 and IFCC 2002/6). Total bilirubin was measured by a modified acid diazo coupling method [Malloy-Evelyn; (Parviainen 1997)], creatinine by a kinetic, colorimetric method with alkaline picrate [method of Jaffe; (Fabiny and Ertingshausen 1971)], and glucose enzymatically with glucose oxidase and a modified Trinder colour reaction (Trinder 1969). Triglyceride, cholesterol and urea concentrations were determined by enzymatic methods (Allain, et al. 1974, Gutmann and Bergmeyer 1974, Wahlefeld 1974).

2.6. RNA isolation and RT-qPCR

Total RNA was extracted from the liver, duodenum, kidney, lung and testes in the subacute study. For the isolation, Sigma GenElute™ Mammalian Total RNA Miniprep Kit was used according to the manufacturer's protocol (Sigma-Aldrich, St. Louis, MO, USA). RNA was then treated with Ambion® TURBO DNA-free™ DNase treatment and removal reagent (Life Technologies, Carlsbad, CA, USA). The concentration of total RNA was measured with a Nanodrop UV Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and RNA purity verified by 260/280 and 260/230 nm ratios. Total RNA was reverse transcribed to cDNA at 50°C for 1 h using M-MLV RT RNase H- Point Mutant (Promega, Fitchburg, WI, USA). For each reaction (25 µl), 100 U of the enzyme and 800 ng of RNA were used. Real-time quantitative PCR (HOT FIREPol® EvaGreen® qPCR Mix Plus (no ROX), Solis Biodyne, Tartu, Estonia) was performed on the RotorGene 3000 instrument (Qiagen, Hilden, Germany) to determine the mRNA levels of the AHR-battery xenobiotic metabolising enzyme genes: *Cyp1a1*, *Cyp1a2*, *Cyp1b1*, *Ahrr*, *Nqo1*, *Tiparp*, *Ugt1a* and *Cyp2b1*. This was carried out by absolute quantification using total RNA amount (20 ng/reaction) for normalization (see Supplementary Table 1 for information on primers) (Bustin 2002,

Tichopad, et al. 2009). If the qRT-PCR result was below the detection limit, a conservative approach was taken and the sample given the value of the limit.

For comparison of gene expression with TCDD-treated Long-Evans (*Turku/AB*; L-E; n=5 per group) and Han-Wistar rats (*Kuopio*; H/W; n=5 per group), existing cDNA samples from a previous study were used (Lindén, et al. 2014). RT-qPCR on these samples was performed with the same primers and in the same conditions, but for statistical analysis, the data were treated separately. This comparison with the S-D rats used in the current study was deemed justified, as both L-E and S-D rats represent TCDD-sensitive rat strains with little difference in their overt responses to TCDD as regards adult exposures [the respective LD50 values are 18 and 43 µg/kg, while for TCDD-resistant H/W rats the LD50 is > 9600 µg/kg (Pohjanvirta, et al. 1993, Stahl, et al. 1992, Unkila, et al. 1994)]. Further, the AHR-mediated induction of xenobiotic-metabolising enzymes is exhibited by all rat strains in the same fashion, including H/W rats (Franc, et al. 2008).

2.7. Thyroxine (T4) detection by ELISA

Thyroxine (T4) levels were measured in sera from the subacute study according to manufacturer's instructions using the Rat Thyroxine T4 ELISA Kit (Cusabio Biotech Co. Ltd, Wuhan, China).

2.8. Retinoid analysis by HPLC

Concentrations of all-*trans*-retinoic acid, 9-*cis*-4-oxo-13,14-dihydro-retinoic acid (9-*cis*-4-oxo-13,14-dh-retinoic acid), 13-*cis*-retinoic acid, 4-hydroxy-all-*trans*-retinoic acid (4-OH-all-*trans*-retinoic acid), retinol and retinyl palmitate were measured in liver, kidney, and serum samples from the subacute study. The different retinoid forms, extracted from tissue homogenates or serum, were separated on HPLC, and detected by UV at 340 nm for retinoic acid derivatives (Schmidt, et al. 2003a), and at 325

nm for retinol and retinyl palmitate (van der Ven, et al. 2009), i.e. the polar and apolar retinoid forms respectively. Briefly, and as reported previously (Schmidt, et al. 2003a), 300 mg of tissue was homogenised with 300 µL of water, and liquid-liquid extraction of retinoids in 400 µL of tissue homogenate or serum was performed with isopropanol. Separation of polar from apolar phase retinoid forms was achieved by solid-phase-extraction using an aminopropyl-phase cartridge (Agilent SampliQ amino, Agilent, Santa Clara, CA, USA). Analytes were separated on a Poroshell 120 EC-C18 column (Agilent) using a binary HPLC system (Agilent 1100 series, Agilent). Retinoid standards included 13-*cis*- and all-*trans*-retinoic acid from Sigma-Aldrich (Madrid, Spain), and 4-OH-all-*trans*-retinoic acid from Toronto Research Chemicals (Toronto, ON, Canada), while acitretin and retinyl acetate (Sigma-Aldrich) were used as internal standards. The limit of detection (LOD) for liver and kidney retinoid concentrations were 0.5 pmol/g for 13-*cis*-retinoic acid, 0.6 pmol/g for all-*trans*-retinoic acid, 1 pmol/g for 9-*cis*-4-oxo-13,14-dh-retinoic acid, and 4-OH-all-*trans*-retinoic acid, and 5.6 pmol/g for retinol and retinyl palmitate (Schmidt, et al. 2003a). LOD for serum retinoid concentrations were 0.3 pmol/ml for all-*trans*-retinoic acid, 0.4 pmol/ml for 13-*cis*-retinoic acid, 0.6 pmol/ml for 9-*cis*-4-oxo-13,14-dh-retinoic acid, and 4.2 pmol/ml for retinol and retinyl palmitate (Schmidt, et al. 2003a).

2.9. Screening of CYP1A1 enzyme activity in H4IIE cells

CYP1A1 enzyme induction potential was screened *in vitro* in the H4IIE rat hepatoma cell line to estimate the efficacy of the novel compounds compared with that of TCDD. The cells were acquired from ATCC (H-4-II-E ATCC® CRL1548™). They were cultured at 37°C and 5% CO₂ in Eagle's Minimum Essential Medium (ATCC, Manassas VA, USA) supplemented with 10% FBS (Sigma-Aldrich, St. Louis, MO, USA). The experiment was performed in a 96-well plate (Greiner Bio-One GmbH, Kremsmünster, Austria). Cells were seeded at 10,000 cells/well and allowed to equilibrate for about 40 h prior to exposures. The outer and corner wells were left without cells and filled with PBS in order to avoid the edge effect. The cells were then exposed for 24 h to 1, 5, 10 or 50 nM of C1, C3 or TCDD in culture

medium, or the vehicle (0.1% of DMSO in culture medium). All exposures were performed in triplicates. CYP1A1 activity was detected with P450-Glo™ CYP1A1 Assay (Promega, Madison, WI, USA) according to manufacturer's instructions. Subsequently, CellTiter-Glo® Luminescent Cell Viability Assay (Promega) was used to confirm that there were no significant differences between the numbers of viable cells in the wells at the time of detection. MycoAlert™ Mycoplasma Detection Kit (Lonza Group Ltd, Basel, Switzerland) was used for parallel cells to ensure that the cells used in the experiment were not infected.

2.10. Data analysis and statistics

In the single-dose study, BW change and relative organ weights (liver, thymus) were statistically assessed only among control and the highest dosage groups of H2 and H4 because of the low number of animals in the middle dose groups. To this end, one-way ANOVA followed by Duncan's new multiple range test were used applying the SPSS Statistics software (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0/24.0. Armonk, NY, USA).

For the subacute toxicity study data of organ weights, clinical chemistry parameters and mRNA abundance, statistical analysis was carried out by one-way ANOVA and Student-Newman-Keuls post-hoc test. If variances were non-homogeneous in ANOVA (as assessed by Levene's test), those values were log-transformed (which restored homogeneity) and then re-analysed by one-way ANOVA. The level of significance in all statistical analyses was set at $p < 0.05$, unless specified otherwise.

Statistical analysis of the mRNA abundance data from the TCDD-treated L-E and H/W rats used for comparison was carried out by Student's t-test for independent samples. The results were verified by Mann-Whitney U test due to small group sizes and some of the data not being normally distributed (as assessed by Shapiro-Wilk's test).

359

360 BW development in the subacute study was statistically analysed using mixed between/within subject
361 two-way ANOVAs. For this purpose, the data were verified for normal distribution by Shapiro-Wilk's
362 test, equality of error variances and covariance matrices was assessed by Levene's and Box's tests,
363 respectively, and the homogeneity of the variances of the differences between all combinations of
364 levels of the within-subjects factor (sphericity) by Mauchly's test. Simple main effects were analysed
365 by univariate ANOVA and the Tukey HSD post-hoc test. The level of significance was set at $p < 0.05$ in
366 all other cases except for Box's test where only values $p < 0.001$ were considered significant.

367

368 Serum thyroxine levels were statistically assessed using Kruskal-Wallis non-parametric ANOVA. As
369 mentioned above, they were determined with an ELISA kit. A scrutiny of the standard curve revealed
370 that the lowest standard yielded absorbances that were incompatible with those of the other ones.
371 Because of this and the fact that we were more interested in possible differences among the groups
372 than actual thyroxine levels *per se*, we decided to utilize the absorbances themselves in the statistical
373 analysis instead of their converted thyroxine concentrations. This approach was statistically justified
374 as we used a non-parametric approach (Kruskal-Wallis ANOVA) based on rank orders of the values in
375 the experimental and control groups. We further verified the methodology with sera from TCDD-
376 sensitive L-E rats collected at 10 days after exposure to 100 µg/kg TCDD or the vehicle (corn oil) (Lindén,
377 et al. 2014). The control samples were run on the same ELISA plate and handled identically to the
378 actual samples, except that the non-parametric test in this case was Mann-Whitney U since only two
379 groups were compared. Based on the absorbance analysis, there was a statistically significant decrease
380 in thyroxine levels caused by TCDD in L-E, which is in line with previous findings (Pohjanvirta, et al.
381 1989).

382

Retinoid concentrations were expressed as mean \pm SD. Pairwise multiple comparisons between exposed and control means were performed by using analysis of variance (ANOVA) and linear contrast tests. Significance was considered for values of $p < 0.05$, and tendency for $p < 0.1$ in R software version 3.2.3, (R Development Core Team, R Foundation for Statistical Computing, Vienna, Austria). Each retinoid was assessed individually. In addition, Box plots were used for verification of normal distribution.

The luminescence data from the *in vitro* CYP1A1 activity assay were analysed in two different ways. First, the concentrations were individually and compound-wise compared with the control by Kruskal-Wallis non-parametric ANOVA, considering the significances asymptotic. Therefore, the significances of the pairwise comparisons were not adjusted. Second, the fold-changes were subjected to two-way ANOVA. Because the original data as well as the transformations attempted (log10, natural logarithm, square root and square) all yielded non-homogeneous variances (Levene's test: $p < 0.001$) and there was slight deviation from normal distribution in one of the datasets (C1, 50 nM; Shapiro-Wilk's test: $p = 0.015$), the significance level for the interaction term was set at $p < 0.001$. Simple main effects were assessed by multiple pairwise comparisons with Bonferroni's adjustment.

3. Results

3.1. Acute toxicity

Acute toxicity was screened by administering single doses of both C2 and C4 at three different dose levels, the highest of which (92.5 mg/ml and 75 mg/ml, respectively) were determined by the solubility of the compounds. The only conspicuous clinical sign of toxicity was watery faeces in one individual rat that received the first low dose (17.5 mg/kg of C2) in the volume of 10 ml/kg, a common side effect of PEG-400 (Hermansky, et al. 1995, Ueda, et al. 2011). Subsequently, the volume administered was lowered to 5 ml/kg for the other rats, which ameliorated the diarrhoea. There were no further clinical signs of toxicity seen during the experiment at any dose levels tested, which is why the highest doses were selected to be used in the repeated dosing experiment. As the number of rats in each group was low in this experiment (n=1–3, except for controls where n=6), data from it should be considered with caution, and statistical evaluation was only performed among control and the highest doses of C2 and C4. However, BW gain at 7 days after exposures appeared to show a slightly delayed trend, reaching statistical significance ($p<0.05$) for 75 mg/ml C4. The dose of 92.5 mg/ml C2 did not differ from either control or 75 mg/ml C4 (Supplementary Table 2). Also, both relative and absolute thymus weights exhibited a decreasing trend, with a statistically significant ($p<0.05$) relative weight loss of 30 % in both high dose groups compared with controls (Supplementary Table 2). Liver weights showed a slight (10 %) decrease in the C4 mid- and both high dose groups when compared with controls, but statistical significance was not attained (Supplementary Table 2).

3.2. Clinical signs of subacute toxicity

For the evaluation of subacute toxicity, C2 and C4 were administered once a day for 5 consecutive days at 100 mg/kg/day and 75 mg/kg/day, respectively. After exposures, the rats were monitored for further 5 days before euthanasia and collection of samples. Contrary to the characteristic wasting syndrome of TCDD, BW gain tended to be only marginally decelerated (Fig. 3). Two-way mixed ANOVA revealed a statistically significant interaction in BW gain between treatment and time ($F[4,28]=3.647$;

p=0.016; partial η^2 =0.343), and subsequent univariate ANOVAs (followed by the Tukey HSD tests) at the three time-points showed that the BW gain of C2 at 9 days (4.7%) was lower than that of control (10.1%; p = 0.049). Further, at repeated exposures, slightly soft faeces were seen in many rats in all groups (including controls) also at 5 ml/kg of PEG-400. Other than those, there were no conspicuous clinical signs of toxicity in either group, apart from peculiar, transient hyperaemia of the ear pinnae (Supplementary Fig. 1). This change appeared on the first day after the end of the 5-day dosing regimen and persisted for 3–4 days. There were 3/5 rats in C2 group and 5/6 rats in C4 group to display this effect. The severity of the hyperaemia varied among individuals, and mostly both ears were affected (6–7/8).

----- Fig. 3 approximately here -----

3.3. Changes in AHR-battery gene expression

In the repeated exposure experiment, *Cyp1a1* gene expression was determined in liver, duodenum, kidney, testis and lung, and in addition *Cyp1a2*, *Cyp1b1*, *Cyp2b1*, *Ahrr*, *Nqo1*, *Tiparp*, and *Ugt1a* mRNA abundances were determined in liver. For comparison of C2 and C4 with TCDD, liver cDNA originating from a previous study (Lindén, et al. 2014) was analysed with the same primers and in the same conditions as the samples from the current study. In the Lindén study, TCDD-sensitive L-E and TCDD-resistant H/W rats were exposed to a single ig dose of 100 μ g/kg TCDD and euthanised on day 10. This comparison was considered justified, as there is little difference in TCDD-sensitivity between adult S-D and L-E rats [the respective LD50 values are 43 and 18 μ g/kg, while for H/W rats the LD50 is > 9600 μ g/kg (Pohjanvirta, et al. 1993, Stahl, et al. 1992, Unkila, et al. 1994)]. Further, induction of xenobiotic-metabolising enzymes is similarly manifested in both sensitive and resistant rat strains (Franc, et al. 2008).

Cyp1a1 gene expression, a sensitive marker for AHR activation, was substantially increased in all examined tissues by C2, and, apart from testis, also by C4 ($p<0.05$; Fig. 4). Increased gene expression by C2 in the liver was additionally measured for the AHR-battery genes *Cyp1a2*, *Cyp1b1*, *Ahrr*, *Nqo1* and *Ugt1a*, but by C4 only for *Cyp1a2* and *Ahrr* ($p<0.05$; Table 1). However, all of the changes were much less pronounced than after a single dose of 100 µg/kg of TCDD. The most conspicuous differences in the induction profiles of TCDD and C2/C4 were discernible in *Cyp1b1*, *Ahrr*, *Nqo1* and *Tiparp*, all of which were markedly induced by TCDD but feebly, if at all, by C2/C4 (Table 1).

----- Fig. 4 approximately here -----

----- Table 1 approximately here -----

3.4. Organ weights

After the subacute toxicity experiment, the thymus, liver, kidneys, spleen and testes of each animal were weighed, and liver, spleen, kidneys, testes and lung were examined histologically. Thymus was the only studied organ where statistically significant changes in weight were seen: both the absolute and relative weights were decreased by C2 and C4 alike. In both groups, the relative weights were about 40% lower than in the control group (40% for C2, and 36% for the C4 group; one-way ANOVA $p<0.001$; Fig. 5). The slight increases in relative testis weights (11% for C2, and 6 % for C4) evaded statistical significance (one-way ANOVA $p=0.068$).

----- Fig. 5 approximately here -----

3.5. Histopathology

In the subacute toxicity study, C2 and C4 administration induced minimal hepatic extramedullary myeloid haematopoiesis (EMH; Fig. 6) (Thoolen, et al. 2010). This was observed in 3/5 C2-treated and in 4/5 C4-treated animals; none was present in controls. The very lenient reaction consisted of some tiny (<10 cells) sinusoidal foci and of small portal or perivascular infiltrates in selected animals. In general, the most prevalent were deeply basophilic nucleated erythrocytes and undifferentiated progenitor cells with lesser numbers of immature granulocytes. In addition to EMH, no other significant lesions were noted; some animals amongst both treatment groups and controls exhibited few mixed or lymphocytic cell infiltrates or parenchymal inflammatory foci (Thoolen, et al. 2010). One C4-treated animal showed a mild (micro- and macrovesicular) fatty change without extramedullary haematopoiesis and one C2-treated animal a focal minimal fatty change with minimal EMH. All spleen samples exhibited minimal to moderate EMH of all three lineages (Cesta 2006). In contrast to the liver, the intensity of EMH in the spleen did not, however, correlate with the treatments (Supplementary Table 3). No significant histopathological alterations were detected in the lungs or in the testes.

----- Fig. 6 approximately here -----

3.6. Clinical chemistry

In the subacute toxicity study, the only marked alteration in serum clinical chemistry variables was a reduction of triglycerides by C2 (44%, one-way ANOVA, $p=0.02$; Fig. 7). C4 had a similar effect, but the 30% decrease caused by it did not reach statistical significance. In addition, there was a statistically significant increase of 86% in the level of 3-HB by C4 (ANOVA $p=0.045$). A similar increase of 58% by C2 was not statistically significant.

----- Fig. 7 approximately here -----

3.7. Thyroxine (T4) levels

Thyroxine levels were measured in sera collected upon termination of the subacute toxicity test. There were no statistically significant differences among the groups (ANOVA $p=0,426$; Supplementary Table 4).

3.8. Retinoid analysis

Analysis of polar and apolar retinoid concentrations in the liver, kidney and serum was performed for the control, C2 and C4 groups after the subacute toxicity experiment. In the liver, statistically significant decreases in concentrations of 4-OH-all-*trans*-retinoic acid, 9-*cis*-4-oxo-13,14-dihydro-retinoic acid, and retinyl palmitate were found in both the C2 and C4 groups, while the concentrations of 13-*cis* retinoic acid and retinol were not significantly affected in either group (Table 2). The observed increase in hepatic all-*trans* retinoic acid concentration was significant in group C2 only. In serum, significant decreases occurred in concentrations of 13-*cis*-retinoic acid, 9-*cis*-4-oxo-13,14-dihydro-retinoic acid and retinyl palmitate in both C2 and C4 groups, while retinol concentration was increased by both compounds, and all-*trans* retinoic acid levels were not affected (Table 2). In the kidney, significant increases were detected in retinol and retinyl palmitate concentrations in both the C2 and C4 groups, while the observed increase in renal all-*trans* retinoic acid level was significant in C2 group only (Table 2). Renal concentrations of 9-*cis*-4-oxo-13,14-dihydro-retinoic acid were not influenced by the treatments.

The magnitudes of effects caused by C2 and C4 in retinoid concentrations were largely comparable. For most retinoid forms analysed, the changes recorded were slightly more pronounced in C2 vs C4

group, in line with the higher dose given of this compound. Two exceptions to this rule were provided by renal retinyl palmitate and serum 13-*cis*-retinoic acid concentrations which were affected clearly more by C4 than C2.

----- Table 2 approximately here -----

3.9. Screening of CYP1A1 enzyme activity *in vitro* in H4IIE cells

The compounds C1 and C3 were screened *in vitro* in the H4IIE rat hepatoma cell line for their CYP1A1 enzyme induction potential, and compared with that of TCDD. The cells were exposed to 1, 5, 10 or 50 nM of either compound or TCDD for 24 h, after which CYP1A1 activity was assessed by a luminescent method. All of the compounds showed a statistically significant induction of CYP1A1 (ANOVA $p < 0.005$), which increased in a dose-dependent fashion (Fig. 8). Apart from the dose level of 1 nM, each concentration of the compounds increased CYP1A1 induction in a statistically significant manner when compared with the control group (Fig. 8). In two-way (compound x concentration) ANOVA on the fold-change data, the interaction term proved significant [$F(6,57)=7.883$, $p=3E-6$, partial $\eta^2=0.454$]. Subsequent analysis of simple main effects showed that at all concentrations but the lowest one (1 nM), TCDD differed from both C1 and C3 in a statistically significant manner ($p < 0.05$).

----- Fig. 8 approximately here -----

4. Discussion

The AHR is notorious for mediating the toxic effects of TCDD and other related environmentally persistent organic pollutants, both in laboratory animals and humans. Based on epidemiological data, exposure to high levels of dioxins in humans is associated with an overall elevation in cancer risk and chloracne, while much lower exposure levels within sensitive time-windows may cause endocrine disruption, altered sex ratios of offspring and lowered quality of sperm (White, et al. 2011). Less evident but still possible adverse health effects include type 2 diabetes and reproductive effects such as increased risk for infertility. In laboratory animals, characteristic adverse effects also include alterations in blood lipids and thyroid function, and immunological effects, but the epidemiological data for these effects in humans remain conflicting (Bastomsky 1977, Fletcher, et al. 2005, Gorski and Rozman 1987, Kerkvliet 2011, Pohjanvirta, et al. 1989, White, et al. 2011). The current consensus is that the adverse effects of dioxins are a consequence of untimely and protracted activation of the AHR, while its appropriate activation is in fact fundamental for normal development and function of all vertebrates, especially for the balanced action of immune system (Bock and Köhle 2006, Denison, et al. 2011, Fernandez-Salguero, et al. 1995, Harrill, et al. 2013). Thus, compounds that could activate the AHR without causing toxicity could have great potential as pharmaceuticals, which could form a basis for novel treatments of diseases in several fields. Here, we characterised toxicological properties of two such candidate compounds, abridged C2 and C4, which are intended as novel selective modulators of the AHR. Their properties were studied in S-D rats, both after a single and 5-day repeated dosing, and in H4IIE cells.

The aim of the single dose experiment was to verify that the acute toxicity of the compounds was so low that they could be administered repeatedly. The experiment confirmed that, as during its performance there were no apparent clinical signs of toxicity. However, at the highest dose of both compounds (n=3), thymus size was significantly diminished and a tendency towards dampened growth was evident. Yet, because the numbers of animals used at each dose level in this experiment were low

in accordance with the modified Up-and-Down procedure applied (OECD 2008), the conclusions drawn from it were regarded as indicative. Therefore, all of the results discussed below are from the 5-day repeated dosing experiment, unless otherwise specified.

Although the exposure period to the compounds in the subacute toxicity experiment was short (5 days), the animals were administered the highest doses practically achievable, and therefore it can be expected to have revealed the short-term toxic potential of the test compounds, in particular as to any sensitive endpoints. While the rats overall tolerated the treatments well, the compounds were not without effect. As assessed by their ability to induce hepatic *Cyp1a1* gene expression, a fairly rapid and highly sensitive marker for AHR activation (Abraham, et al. 1988), both C2 and C4 appeared to be effective compounds, although apparently either not as much so as TCDD, or the effect was not equally long-lasting. A single dose of 0.1 mg/kg TCDD used previously in the study by Lindén et al. (2014) brought about, even 10 days after the exposure, more prominent hepatic induction of *Cyp1a1*: 1100-fold in the TCDD-sensitive L-E strain and 860-fold in the TCDD-resistant H/W strain. Here, doses of 100 mg/kg/day and 75 mg/kg/day for C2 and C4, respectively, administered daily on days 0–4, resulted in 370- and 140-fold inductions, when similarly measured in samples taken on day 9 (the molecular weights of C2 and C4 are 30–50% higher than that of TCDD). However, the true *in vivo* induction potencies of C2 and C4 may be greater than suggested by the findings of the present study, since the 5-day recovery period included may have markedly influenced the resultant gene expression levels measured. In support of this notion, 1–50 nM concentrations of C1 and especially C3 (the respective, active metabolites of C2 and C4, intended for *in vitro* assays) induced responses closer to the same fold-range as TCDD in the 24h CYP1A1 enzyme activity screening assay in the H4IIE rat hepatoma cell line *in vitro* (Fig. 8). Moreover, in our previous *in vivo* study, even a single dose of 4 mg/kg C2 induced hepatic *Cyp1a1* expression 1700-fold compared with controls, when liver was sampled already at 28 h after exposure (Mahiout and Pohjanvirta 2016). Collectively, these findings imply a rapid and probably inducible elimination of C2 and C4 in S-D rats, with an elimination half-life within a range of hours to a

couple of days for repeated exposure. This may also account for the variability seen in *Cyp1a1* induction data (Fig. 4), reflecting inter-individual differences in elimination rates of the compounds.

In addition to *Cyp1a1*, both compounds also induced here several other AHR-battery genes of xenobiotic metabolism, but the induction profiles were distinct for TCDD and C2/C4 (Table 1). In this regard, especially *Ahrr* and *Cyp1b1* clearly stood out. Of special interest is also the lack of *Ugt1* induction by C2/C4, because the reduction in serum thyroxine caused by TCDD chiefly emanates from accelerated thyroxine catabolism by liver UGT1A6 (Nishimura, et al. 2005), and C2/C4 failed to influence circulating thyroxine concentrations (see below). Overall, the results resembled those of *Cyp1a1* activation in the sense that C2 appeared somewhat more effective than C4, and TCDD clearly more so than the two novel compounds. The difference between C2 and C4 is likely, at least partly, due to the dissimilarity of the doses used, which were dictated by the solubility of the compounds. This view is reinforced by the *in vitro* CYP1A1 induction results presented here, as well as by our yet unpublished *in vitro* data on these compounds (manuscript in preparation), which revealed that in fact C3 consistently appeared somewhat more effective than C1. As for the differences between C2/C4 and TCDD, a likely explanation lies in pharmacokinetics. After all, TCDD is well-known for its very low biodegradability, also in rats (Pohjanvirta, et al. 1990), which in turn leads to persistent activation of the AHR, enabling major toxicities to emerge. Hence, for pharmaceutical use, C2 and C4 appear to be much better-suited in this respect.

The likelihood that C2 and C4 are metabolised and excreted much more efficiently than TCDD should not lead to the assumption that they would be without other discernible effects than activation of metabolic pathways. Indeed, there were also other characteristic effects that appear to be quite similar between both C2/C4 and TCDD, even if somewhat less pronounced by the novel compounds: thymic atrophy, changes in tissue retinoid (vitamin A) concentrations and, as we previously reported for C2, novel food avoidance (Fletcher, et al. 2001, Gupta, et al. 1973, Harris, et al. 1973, Lensu, et al. 2011a,

Mahiout and Pohjanvirta 2016, Tuomisto, et al. 2000). Thymic atrophy is one of the most consistent and uniform effects of TCDD across mammalian species (Pohjanvirta and Tuomisto 1994). It mainly stems from depletion of small immature cortical thymocytes (Vos, et al. 1974) by a mechanism which may involve impeded maturation of T-lymphocyte precursors (Greenlee, et al. 1985, Holladay, et al. 1991), enhanced apoptosis (McConkey, et al. 1988), and impaired thymic seeding by prothymocytes (Fine, et al. 1990). TCDD also weakens both cell-mediated and humoral-mediated immunity, increasing susceptibility to infectious diseases and transplanted tumours (Luebke, et al. 2006, Pohjanvirta and Tuomisto 1994).

As to retinoid homeostasis, retinol and retinyl palmitate concentrations in the liver, kidney and serum were affected in the same manner by C2 and C4. Of these, the hepatic and renal changes, along with the substantial diminution in 9-*cis*-4-oxo-13,14-dihydro-retinoic acid levels in the liver, were also reminiscent of those seen after short-term TCDD exposure in male rats (Hoegberg, et al. 2003, Nilsson, et al. 2000, Schmidt, et al. 2003b). However, the decrease detected in serum retinyl palmitate concentration in C2- and C4-treated rats is not a typical effect of TCDD, and high TCDD doses have been reported to elevate serum all-*trans*-retinoic acid levels (Hoegberg, et al. 2003, Nilsson, et al. 2000, Schmidt, et al. 2003b), while this retinoid species remained unaltered following C2 or C4 exposure. It should also be noted that there are not enough data in the literature on the effect of TCDD on several of the retinoic acid derivatives in the tissues that were analysed in the present study. In particular, data are lacking on the effect of TCDD on 4-OH-all-*trans*- or 13-*cis*-retinoic acid in rat tissues. Therefore, no firm conclusions can be drawn yet on the full extent to which the alterations induced by C2 and C4 resemble those of TCDD.

All of the effects mentioned above are classified as type I, and are thus responses that are similar in both TCDD-sensitive L-E and TCDD-resistant H/W rat strains (Pohjanvirta, et al. 2011). In this rat strain model of TCDD toxicity, TCDD resistance is based on an altered transactivation domain structure in the

AHR of the resistant H/W strain. This change results in an at least 100-fold difference in TCDD doses required to elicit certain responses in L-E vs. H/W rats (type II effects). As a corollary, it means that type I effects, which emerge at the same doses in both strains, are robust to structural variations in AHR transactivation domain and thereby represent more generic AHR-mediated impacts. As a rule, type II effects occur at higher doses of TCDD than type I effects, although exceptions exist. In this light, it is interesting that there are also several typical toxic effects of TCDD that are lacking altogether with C2 and C4, at least at the doses used here: hypercholesterolemia and reduced plasma thyroxine levels (both type I effects); acute lethality, wasting syndrome, grave liver and testis lesions, hypoglycaemia, and elevated plasma FFA levels (all type II effects) (Pohjanvirta, et al. 2011, Viluksela, et al. 1999). Hence, these novel AHR activators bring about only a subset of the response spectrum previously reported to TCDD, and all those effects belong to type I category. Whether any of type II responses would manifest if higher doses of C2 or C4 could be administered is a matter of speculation. However, the slight downward tendency recorded in BWs in the present study might suggest that the existence of early alterations in the adverse outcome pathway that ultimately culminates to the wasting syndrome cannot be totally ruled out.

On the other hand, it is noteworthy that C2 and C4 also induced effects that have not been reported with TCDD. These included a conspicuous ear hyperaemia, minimal EMH in the liver, a reduction of serum triglycerides and an increase of serum 3-HB. The ear hyperaemia appears perplexing, as it has not been reported previously as a clinical response to AHR activators. There was no visible injury to the skin, nor any clinical sign of infection. The hyperaemia might suggest a transient disturbance of either systemic or local thermoregulation, or be due to changes in blood pressure or vasodilatation. Further studies are needed to resolve its pathogenesis. EMH has been reported on post-natal day 14 in the livers of mice exposed to TCDD *in utero* (Weinstein, et al. 2008), but to the best of our knowledge, not in animals exposed to TCDD at adult age. However, a multitude of factors (including xenobiotics) which cause e.g. local hypoxia, bone marrow failure or myelotoxicity can elicit it in laboratory animals,

most frequently in spleen but also in liver (Chiu, et al. 2015). In the present case, it is tempting to link it with the auricular hyperaemia, because both could represent a response to tissue hypoxia. In serum, the concomitant decrease of triglycerides and elevation of 3-HB point to enhanced β -oxidation at the expense of lowered *de novo* fatty acid biosynthesis in the liver. The interference of TCDD with hepatic lipid metabolism is unclear at present, because there is evidence in favour of accelerated (Muzi, et al. 1989, Potter, et al. 1986), decelerated (Christian, et al. 1986), and unaltered (Tomaszewski, et al. 1988) β -oxidation rate in rats treated with TCDD at doses capable of causing the wasting syndrome. In any case, serum ketone bodies typically remain unaffected (Pohjanvirta and Tuomisto, 1994), and thus these novel AHR activators stand out from the dioxin-like toxicity pattern in this respect.

Moreover, there are some characteristic adverse effects common to TCDD exposure that we did not look into in these experiments due to technical reasons, and thus information about the effects of C2 and C4 on these is, for the time being, lacking completely. These include further effects on the endocrine system, such as changes in testosterone, insulin or melatonin levels; changes in the degree of oxidative stress in various tissues; bone and tooth lesions; immuno- and developmental toxicity; and carcinogenicity. In adult rats, reduction of serum thyroxine appears to be one of the most sensitive endocrine indicators of exposure to TCDD with an ED_{50} between 1 and 5 $\mu\text{g}/\text{kg}$ in S-D rats (Viluksela, et al. 2004). Hence, the fact that its levels appear to be unaffected by C2 and C4 could predict that there would be few if any effects on other hormone levels either, but this should naturally be tested in the future, as well as the possible existence of the other effects that were missing here.

In addition to the AHR mediating immunotoxic effects, it has also been identified as part of a molecular pathway of physiological immune responses, and thus as a target for immunomodulatory therapies [reviewed in (Zhu, et al. 2014)]. Disease models in which AHR modulation has been suggested as a possible target include, for instance, cancer, Crohn's disease, ulcerative colitis, diabetes, MS and inflammatory skin conditions such as atopic dermatitis (Benson and Shepherd 2011, Díaz-Díaz, et al.

2016, Furumatsu, et al. 2011, Haas, et al. 2016, Jin, et al. 2014, Kerkvliet, et al. 2009, Quintana, et al. 2010, Singh, et al. 2007, Van Den Bogaard, et al. 2013). Although the mechanisms of action of the parent compounds of C1 and C3, laquinimod and tasquinimod, are not yet fully elucidated, they are recognised as immunomodulatory compounds (Raymond, et al. 2014, Varrin-Doyer, et al. 2014). Moreover, the immunomodulatory mode of action of laquinimod, which produces low but persistent levels of C1, has been shown to be AHR dependent in the mouse Experimental Autoimmune Encephalomyelitis (EAE) MS model (Berg, et al. 2016, European Medicines Agency 2014, Kaye, et al. 2016). Further, C1 is a more potent inhibitor of disease development in the EAE model than laquinimod (European Medicines Agency 2014). Finally, substantially higher levels of C1 are generated *in vivo* from C2 than from laquinimod (unpublished results). Therefore, it would be of high interest to study the likely effects that C2 and C4 have on the immune system in the future. So far, the only information is from the EAE model in rats, where C2 (total dose 4 mg/kg, sc) efficiently prevented EAE development (Pettersson 2012) and from unpublished data on its ameliorating effects in the dextran sulfate sodium-induced colitis model in mice (1 mg/kg, po).

In conclusion, it appears clear that these novel compounds are potent activators of the AHR, but lack some major characteristic toxic effects of TCDD. In addition, overall their observed effect profiles seem distinct from that of TCDD, and pharmacokinetics is likely to play a role in this. It is also possible that they have lower binding affinities to the AHR, or occupy a different position in the ligand-binding domain of the protein (Denison, et al. 2011); these would be interesting to explore in the future. Whether these compounds are capable of causing type II effects of TCDD at all would also be worth studying further. Nevertheless, based on our findings, both C2 and C4 appear to represent promising new selective AHR modulators.

721 **Supplementary material description**

722 **Supplementary Table 1** Primer sequences and amplification efficiencies in RT-qPCR runs.

723 **Supplementary Table 2** Body weight gain and relative thymus and liver weights in the acute toxicity
724 study.

725 **Supplementary Table 3** Observed EMH in the spleen across groups in the subacute toxicity study.

726 **Supplementary Table 4** Serum thyroxine absorbances in the subacute toxicity study.

727 **Supplementary Fig. 1** Photos of transient hyperaemia in the ears after 5-day repeated dosing.

728

729

730 **Acknowledgements**

731 The work was financially supported by Academy of Finland (Grant no. 261232; to RP) and University of
732 Helsinki Doctoral Programme in Food Chain and Health of the Doctoral School in Environmental, Food
733 and Biological Sciences (to SM). We further wish to acknowledge Susanna Lukkarinen for her valuable
734 technical contribution in processing samples and performing RT-qPCR. The staff at Laboratory Animal
735 Centre (LAC) of the University of Helsinki is thanked for their cooperation and help with practicalities;
736 we especially thank Leena Liesirova, Anna Meller, Virpi Ahokas and Lea Karvonen for having provided
737 help whenever needed.

738

- 740 Abraham, K., Krowke, R., Neubert, D., 1988. Pharmacokinetics and biological activity of 2,3,7,8-
741 tetrachlorodibenzo-p-dioxin - 1. Dose-dependent tissue distribution and induction of hepatic
742 ethoxyresorufin O-deethylase in rats following a single injection. *Arch. Toxicol.* 62, 359-368.
- 743 Allain, C.C., Poon, L.S., Chan, C.S.G., 1974. Enzymatic determination of total serum cholesterol. *Clin.*
744 *Chem.* 20, 470-475.
- 745 Arsenescu, R., Arsenescu, V., Zhong, J., Nasser, M., Melinte, R., Dingle, R.W.C., Swanson, H., De
746 Villiers, W.J., 2011. Role of the xenobiotic receptor in inflammatory bowel disease. *Inflammatory*
747 *Bowel Dis.* 17, 1149-1162.
- 748 Bastomsky, C.H., 1977. Enhanced thyroxine metabolism and high uptake goiters in rats after a single
749 dose of 2,3,7,8-tetrachlorodibenzo-p-dioxin. *Endocrinology* 101, 292-296.
- 750 Beischlag, T.V., Morales, J.L., Hollingshead, B.D., Perdew, G.H., 2008. The aryl hydrocarbon receptor
751 complex and the control of gene expression. *Crit. Rev. Eukaryotic Gene Expr.* 18, 207-250.
- 752 Benson, J.M., Shepherd, D.M., 2011. Aryl hydrocarbon receptor activation by TCDD reduces
753 inflammation associated with Crohn's disease. *Toxicol. Sci.* 120, 68-78.
- 754 Berg, J., Mahmoudjanlou, Y., Duscha, A., Massa, M.G., Thöne, J., Esser, C., Gold, R., Haghighi, A.,
755 2016. The immunomodulatory effect of laquinimod in CNS autoimmunity is mediated by the aryl
756 hydrocarbon receptor. *J. Neuroimmunol.* 298, 9-15.
- 757 Bock, K.W., Köhle, C., 2006. Ah receptor: Dioxin-mediated toxic responses as hints to deregulated
758 physiologic functions. *Biochem. Pharmacol.* 72, 393-404.
- 759 Bustin, S.A., 2002. Quantification of mRNA using real-time reverse transcription PCR (RT-PCR): Trends
760 and problems. *J. Mol. Endocrinol.* 29, 23-39.
- 761 Cesta, M.F., 2006. Normal structure, function, and histology of the spleen. *Toxicol. Pathol.* 34, 455-
762 465.
- 763 Chiu, S.-., Liu, H.-., Chen, C.-., Chen, P.-., Liu, M.-., Lin, S.-., Chang, K.-., 2015. Extramedullary
764 hematopoiesis (EMH) in laboratory animals: Offering an insight into stem cell research. *Cell*
765 *Transplant.* 24, 349-366.
- 766 Christian, B.J., Menahan, L.A., Peterson, R.E., 1986. Intermediary metabolism of the mature rat
767 following 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment. *Toxicol. Appl. Pharmacol.* 83, 360-378.
- 768 Denison, M.S., Soshilov, A.A., He, G., Degroot, D.E., Zhao, B., 2011. Exactly the same but different:
769 Promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin)
770 receptor. *Toxicol. Sci.* 124, 1-22.
- 771 Díaz-Díaz, C.J., Ronnekleiv-Kelly, S.M., Nukaya, M., Geiger, P.G., Balbo, S., Dator, R., Megna, B.W.,
772 Carney, P.R., Bradfield, C.A., Kennedy, G.D., 2016. The aryl hydrocarbon receptor is a repressor of
773 inflammation-associated colorectal tumorigenesis in mouse. *Ann. Surg.* 264, 429-435.
- 774 Esser, C., Rannug, A., Stockinger, B., 2009. The aryl hydrocarbon receptor in immunity. *Trends*
775 *Immunol.* 30, 447-454.

776 European Medicines Agency, 2014. EMA/451905/2014 - Committee for Medicinal Products for
 777 Human
 778 Use (CHMP) Nerventra, laquinimod.
 779 [http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002546/WC500171788.pdf)
 780 [_Public_assessment_report/human/002546/WC500171788.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002546/WC500171788.pdf), May 2014.

781 Fabiny, D.L., Ertingshausen, G., 1971. Automated reaction-rate method for determination of serum
 782 creatinine with the CentrifChem. Clin. Chem. 17, 696-700.

783 Fernandez-Salguero, P., Pineau, T., Hilbert, D.M., McPhail, T., Lee, S.S.T., Kimura, S., Nebert, D.W.,
 784 Rudikoff, S., Ward, J.M., Gonzalez, F.J., 1995. Immune system impairment and hepatic fibrosis in mice
 785 lacking the dioxin-binding Ah receptor. Science 268, 722-726.

786 Fine, J.S., Silverstone, A.E., Gasiewicz, T.A., 1990. Impairment of prothymocyte activity by 2,3,7,8-
 787 tetrachlorodibenzo-p-dioxin. J. Immunol. 144, 1169-1176.

788 Fletcher, N., Hanberg, A., Håkansson, H., 2001. Hepatic vitamin A depletion is a sensitive marker of
 789 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) exposure in four rodent species. Toxicol. Sci. 62, 166-
 790 175.

791 Fletcher, N., Wahlström, D., Lundberg, R., Nilsson, C.B., Nilsson, K.C., Stockling, K., Hellmold, H.,
 792 Håkansson, H., 2005. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) alters the mRNA expression of
 793 critical genes associated with cholesterol metabolism, bile acid biosynthesis, and bile transport in rat
 794 liver: A microarray study. Toxicol. Appl. Pharmacol. 207, 1-24.

795 Franc, M.A., Moffat, I.D., Boutros, P.C., Tuomisto, J.T., Tuomisto, J., Pohjanvirta, R., Okey, A.B., 2008.
 796 Patterns of dioxin-altered mRNA expression in livers of dioxin-sensitive versus dioxin-resistant rats.
 797 Arch. Toxicol. 82, 809-830.

798 Fujii-Kuriyama, Y., Kawajiri, K., 2010. Molecular mechanisms of the physiological functions of the aryl
 799 hydrocarbon (dioxin) receptor, a multifunctional regulator that senses and responds to
 800 environmental stimuli. Proc. Jpn. Acad. Ser. B Phys. Biol. Sci. 86, 40-53.

801 Furumatsu, K., Nishiumi, S., Kawano, Y., Ooi, M., Yoshie, T., Shiomi, Y., Kutsumi, H., Ashida, H., Fujii-
 802 Kuriyama, Y., Azuma, T., Yoshida, M., 2011. A role of the aryl hydrocarbon receptor in attenuation of
 803 colitis. Dig. Dis. Sci. 56, 2532-2544.

804 Gorski, J.R., Rozman, K., 1987. Dose-response and time course of hypothyroxinemia and
 805 hypoinsulinemia and characterization of insulin hypersensitivity in 2,3,7,8-tetrachlorodibenzo-p-
 806 dioxin (TCDD)-treated rats. Toxicology 44, 297-307.

807 Greenlee, W.F., Dold, K.M., Irons, R.D., Osborne, R., 1985. Evidence for direct action of 2,3,7,8-
 808 tetrachlorodibenzo-p-dioxin (TCDD) on thymic epithelium. Toxicol. Appl. Pharmacol. 79, 112-120.

809 Gupta, B.N., Vos, J.G., Moore, J.A., 1973. Pathologic effects of 2,3,7,8 tetrachlorodibenzo p dioxin in
 810 laboratory animals. Environ. Health Perspect. 5, 125-140.

811 Gutmann, I., Bergmeyer, H.U., 1974. Determination of urea with glutamate dehydrogenase as
 812 indicator enzyme, in: Bergmeyer, H.U. (Ed.), Methods of Enzymatic Analysis, 2nd English ed. Acad.
 813 Press, New York, NY, U.S.A., pp. 1794-1798.

814 Haas, K., Weighardt, H., Deenen, R., Köhrer, K., Clausen, B., Zahner, S., Boukamp, P., Bloch, W.,
815 Krutmann, J., Esser, C., 2016. Aryl Hydrocarbon Receptor in Keratinocytes Is Essential for Murine
816 Skin Barrier Integrity. *J. Invest. Dermatol.*

817 Hahn, M.E., Karchner, S.I., 2011. Structural and Functional Diversification of AHRs during Metazoan
818 Evolution, in: Pohjanvirta, R. (Ed.), *The AH Receptor in Biology and Toxicology*. John Wiley & Sons,
819 Inc., Hoboken, NJ, USA, pp. 387-403.

820 Hankinson, O., 2016. The role of AHR-inducible cytochrome P450s in metabolism of polyunsaturated
821 fatty acids. *Drug Metab. Rev.* 48, 342-350.

822 Harrill, J.A., Hukkanen, R.R., Lawson, M., Martin, G., Gilger, B., Soldatow, V., LeCluyse, E.L., Budinsky,
823 R.A., Rowlands, J.C., Thomas, R.S., 2013. Knockout of the aryl hydrocarbon receptor results in distinct
824 hepatic and renal phenotypes in rats and mice. *Toxicol. Appl. Pharmacol.* 272, 503-518.

825 Harris, M.W., Moore, J.A., Vos, J.G., Gupta, B.N., 1973. General biological effects of TCDD in
826 laboratory animals. *Environ. Health Perspect.* 5, 101-109.

827 Hermansky, S.J., Neptun, D.A., Loughran, K.A., Leung, H.W., 1995. Effects of polyethylene glycol 400
828 (PEG 400) following 13 weeks of gavage treatment in fischer-344 rats. *Food Chem. Toxicol.* 33, 139-
829 149.

830 Hoegberg, P., Schmidt, C.K., Nau, H., Ross, A.C., Zolfaghari, R., Fletcher, N., Trossvik, C., Nilsson, C.B.,
831 Håkansson, H., 2003. 2,3,7,8-Tetrachlorodibenzo-p-dioxin induces lecithin: Retinol acyltransferase
832 transcription in the rat kidney. *Chem. -Biol. Interact.* 145, 1-16.

833 Holladay, S.D., Lindstrom, P., Blaylock, B.L., Comment, C.E., Germolec, D.R., Heindell, J.J., Luster, M.I.,
834 1991. Perinatal thymocyte antigen expression and postnatal immune development altered by
835 gestational exposure to tetrachlorodibenzo-P-dioxin (TCDD). *Teratology* 44, 385-393.

836 Hu, W., Sorrentino, C., Denison, M.S., Kolaja, K., Fielden, M.R., 2007. Induction of Cyp1a1 is a
837 nonspecific biomarker of aryl hydrocarbon receptor activation: Results of large scale screening of
838 pharmaceuticals and toxicants in vivo and in vitro. *Mol. Pharmacol.* 71, 1475-1486.

839 Isaacs, J.T., Pili, R., Qian, D.Z., Dalrymple, S.L., Garrison, J.B., Kyprianou, N., Björk, A., Olsson, A.,
840 Leanderson, T., 2006. Identification of ABR-215050 as lead second generation quinoline-3-
841 carboxamide anti-angiogenic agent for the treatment of prostate cancer. *Prostate* 66, 1768-1778.

842 Jin, U.H., Lee, S.O., Pfent, C., Safe, S., 2014. The aryl hydrocarbon receptor ligand omeprazole inhibits
843 breast cancer cell invasion and metastasis. *BMC Cancer* 14:498.

844 Kaye, J., Piryatinsky, V., Birnberg, T., Hingaly, T., Raymond, E., Kashi, R., Amit-Romach, E., Caballero,
845 I.S., Towfic, F., Ator, M.A., Rubinstein, E., Laifenfeld, D., Orbach, A., Shinar, D., Marantz, Y., Grossman,
846 I., Knappertz, V., Hayden, M.R., Laufer, R., 2016. Laquinimod arrests experimental autoimmune
847 encephalomyelitis by activating the aryl hydrocarbon receptor. *PNAS*.

848 Kerkvliet, N.I., Stepan, L.B., Vorachek, W., Oda, S., Farrer, D., Wong, C.P., Pham, D., Mourich, D.V.,
849 2009. Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases
850 Foxp3 + T cells in pancreatic lymph nodes. *Immunotherapy* 1, 539-547.

851 Kerkvliet, N.I., 2011. TCDD, AHR, and Immune Regulation, in: Pohjanvirta, R. (Ed.), *The AH Receptor in*
852 *Biology and Toxicology*. John Wiley & Sons, Inc., Hoboken, NJ, U.S.A., pp. 277-284.

853 Kiss, E.A., Vonarbourg, C., Kopfmann, S., Hobeika, E., Finke, D., Esser, C., Diefenbach, A., 2011.
854 Natural aryl hydrocarbon receptor ligands control organogenesis of intestinal lymphoid follicles.
855 Science 334, 1561-1565.

856 Lampen, A., Meyer, S., Arnhold, T., Nau, H., 2000. Metabolism of vitamin A and its active metabolite
857 all-trans-retinoic acid in small intestinal enterocytes. J. Pharmacol. Exp. Ther. 295, 979-985.

858 Lee, J.S., Cella, M., McDonald, K.G., Garlanda, C., Kennedy, G.D., Nukaya, M., Mantovani, A., Kopan,
859 R., Bradfield, C.A., Newberry, R.D., Colonna, M., 2012. AHR drives the development of gut ILC22 cells
860 and postnatal lymphoid tissues via pathways dependent on and independent of Notch. Nat.
861 Immunol. 13, 144-152.

862 Lensu, S., Tuomisto, J.T., Tuomisto, J., Pohjanvirta, R., 2011a. Characterization of the 2,3,7,8-
863 tetrachlorodibenzo-p-dioxin (TCDD)-provoked strong and rapid aversion to unfamiliar foodstuffs in
864 rats. Toxicology 283, 140-150.

865 Lindén, J., Lensu, S., Pohjanvirta, R., 2014. Effect of 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) on
866 hormones of energy balance in a TCDD-sensitive and a TCDD-resistant rat strain. Int. J. Mol. Sci. 15,
867 13938-13966.

868 Luebke, R.W., Chen, D.H., Dietert, R., Yang, Y., King, M., Luster, M.I., 2006. The comparative
869 immunotoxicity of five selected compounds following developmental or adult exposure. J. Toxicol.
870 Environ. Health Part B 9, 1-26.

871 Ma, Q., 2011. Overview of AHR Functional Domains and the Classical AHR Signaling Pathway:
872 Induction of Drug Metabolizing Enzymes, in: Pohjanvirta, R. (Ed.), The AH Receptor in Biology and
873 Toxicology. John Wiley & Sons, Inc., Hoboken, NJ, USA, pp. 33-45.

874 Mahiout, S., Pohjanvirta, R., 2016. Aryl hydrocarbon receptor agonists trigger avoidance of novel
875 food in rats. Physiol. Behav. 167, 49-59.

876 Mandal, P.K., 2005. Dioxin: A review of its environmental effects and its aryl hydrocarbon receptor
877 biology. J. Comp. Physiol. B. 175, 221-230.

878 McConkey, D.J., Hartzell, P., Duddy, S.K., Håkansson, H., Orrenius, S., 1988. 2,3,7,8-
879 Tetrachlorodibenzo-p-dioxin kills immature thymocytes by Ca²⁺-mediated endonuclease activation.
880 Science 242, 256-259.

881 McMillan, B.J., Bradfield, C.A., 2007. The aryl hydrocarbon receptor sans xenobiotics: Endogenous
882 function in genetic model systems. Mol. Pharmacol. 72, 487-498.

883 Moura-Alves, P., Faé, K., Houthuys, E., Dorhoi, A., Kreuchwig, A., Furkert, J., Barison, N., Diehl, A.,
884 Munder, A., Constant, P., Skrahina, T., Gühlich-Bornhof, U., Klemm, M., Koehler, A.-., Bandermann,
885 S., Goosmann, C., Mollenkopf, H.-., Hurwitz, R., Brinkmann, V., Fillatreau, S., Daffe, M., Tümmler, B.,
886 Kolbe, M., Oschkinat, H., Krause, G., Kaufmann, S.H.E., 2014. AhR sensing of bacterial pigments
887 regulates antibacterial defence. Nature 512, 387-392.

888 Muzi, G., Gorski, J.R., Rozman, K., 1989. Mode of metabolism is altered in 2,3,7,8-tetrachlorodibenzo-
889 p-dioxin (TCDD)-treated rats. Toxicol. Lett. 47, 77-86.

890 Nebert, D.W., Dalton, T.P., Okey, A.B., Gonzalez, F.J., 2004. Role of aryl hydrocarbon receptor-
891 mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J. Biol. Chem. 279,
892 23847-23850.

893 Nilsson, C.B., Hoegberg, P., Trossvik, C., Azais-Braesco, V., Blaner, W.S., Fex, G., Harrison, E.H., Nau,
894 H., Schmidt, C.K., van Bennekum, A.M., Hakansson, H., 2000. 2,3,7,8-Tetrachlorodibenzo-p-dioxin
895 increases serum and kidney retinoic acid levels and kidney retinol esterification in the rat. *Toxicol.*
896 *Appl. Pharmacol.* 169, 121-131.

897 Nishimura, N., Yonemoto, J., Miyabara, Y., Fujii-Kuriyama, Y., Tohyama, C., 2005. Altered thyroxin and
898 retinoid metabolic response to 2,3,7,8-tetrachlorodibenzo-p-dioxin in aryl hydrocarbon receptor-null
899 mice. *Arch. Toxicol.* 79, 260-267.

900 OECD, 2008. *Test no. 425: Acute Oral Toxicity: Up-and-Down Procedure*, OECD Guidelines for the
901 Testing of Chemicals, Section 4. OECD Publishing, Paris.

902 Parviainen, M.T., 1997. A modification of the acid diazo coupling method (Malloy-Evelyn) for the
903 determination of serum total bilirubin. *Scand. J. Clin. Lab. Invest.* 57, 275-280.

904 Pettersson, L., 2012. 1,2-Dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as AHR Activators.
905 WO2012/050500A1.

906 Pohjanvirta, R., Kulju, T., Morselt, A.F.W., Tuominen, R., Juvonen, R., Rozman, K., Männistö, P.,
907 Collan, Y., Sainio, E.-., Tuomisto, J., 1989. Target tissue morphology and serum biochemistry following
908 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure in a TCDD-susceptible and a TCDD-resistant rat
909 strain. *Fundam. Appl. Toxicol.* 12, 698-712.

910 Pohjanvirta, R., Tuomisto, J., 1994. Short-term toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in
911 laboratory animals: Effects, mechanisms, and animal models. *Pharmacol. Rev.* 46, 483-549.

912 Pohjanvirta, R., Unkila, M., Tuomisto, J., 1993. Comparative acute lethality of 2,3,7,8-
913 tetrachlorodibenzo-p-dioxin (TCDD), 1,2,3,7,8-pentachlorodibenzo-p-dioxin and 1,2,3,4,7,8-
914 hexachlorodibenzo-p-dioxin in the most TCDD-susceptible and the most TCDD-resistant rat strain.
915 *Pharmacol. Toxicol.* 73, 52-56.

916 Pohjanvirta, R., Vartiainen, T., Uusi-Rauva, A., Monkkonen, J., Tuomisto, J., 1990. Tissue distribution,
917 Metabolism, and excretion of 14c-tcdd in a tcdd-susceptible and a tcdd-resistant rat strain.
918 *Pharmacol. Toxicol.* 66, 93-100.

919 Pohjanvirta, R., Korkalainen, M., Moffat, I.D., Boutros, P.C., Okey, A.B., 2011. Role of the AHR and its
920 Structure in TCDD Toxicity, in: Pohjanvirta, R. (Ed.), *The AH Receptor in Biology and Toxicology*. John
921 Wiley & Sons, Inc., Hoboken, NJ, USA, pp. 179-196.

922 Polman, C., Barkhof, F., Sandberg-Wollheim, M., Linde, A., Nordle, O., Nederman, T., 2005. Treatment
923 with laquinimod reduces development of active MRI lesions in relapsing MS. *Neurology* 64, 987-991.

924 Potter, C.L., Menahan, L.A., Peterson, R.E., 1986. Relationship of alterations in energy metabolism to
925 hypophagia in rats treated with 2,3,7,8-tetrachlorodibenzo-P-dioxin. *Toxicol. Sci.* 6, 89-97.

926 Quintana, F.J., Basso, A.S., Iglesias, A.H., Korn, T., Farez, M.F., Bettelli, E., Caccamo, M., Oukka, M.,
927 Weiner, H.L., 2008. Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor.
928 *Nature* 453, 65-71.

929 Quintana, F.J., Murugaiyan, G., Farez, M.F., Mitsdoerffer, M., Tukupah, A.-., Burns, E.J., Weiner, H.L.,
930 2010. An endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress
931 experimental autoimmune encephalomyelitis. *Proc. Natl. Acad. Sci. U. S. A.* 107, 20768-20773.

932 Raymond, E., Dalgleish, A., Damber, J.-., Smith, M., Pili, R., 2014. Mechanisms of action of
933 tasquinimod on the tumour microenvironment. *Cancer Chemother. Pharmacol.* 73, 1-8.

934 Safe, S., Lee, S.-., Jin, U.-., 2013. Role of the aryl hydrocarbon receptor in carcinogenesis and potential
935 as a drug target. *Toxicol. Sci.* 135, 1-16.

936 Schmidt, C.K., Brouwer, A., Nau, H., 2003a. Chromatographic analysis of endogenous retinoids in
937 tissues and serum. *Anal. Biochem.* 315, 36-48.

938 Schmidt, C.K., Hoegberg, P., Fletcher, N., Nilsson, C.B., Trossvik, C., Håkansson, H., Nau, H., 2003b.
939 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) alters the endogenous metabolism of all-trans-retinoic
940 acid in the rat. *Arch. Toxicol.* 77, 371-383.

941 Schumann, G., Bonora, R., Ceriotti, F., Ferard, G., Ferrero, C.A., Franck, P.F., Gella, F.J., Hoelzel, W.,
942 Jorgensen, P.J., Kanno, T., Kessner, A., Klauke, R., Kristiansen, N., Lessinger, J.M., Linsinger, T.P.,
943 Misaki, H., Panteghini, M., Pauwels, J., Schiele, F., Schimmel, H.G., Weidemann, G., Siekmann, L.,
944 International Federation of Clinical Chemistry and Laboratory Medicine, 2002a. IFCC primary
945 reference procedures for the measurement of catalytic activity concentrations of enzymes at 37
946 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 4. Reference
947 procedure for the measurement of catalytic concentration of alanine aminotransferase. *Clin. Chem.*
948 *Lab. Med.* 40, 718-724.

949 Schumann, G., Bonora, R., Ceriotti, F., Ferard, G., Ferrero, C.A., Franck, P.F., Gella, F.J., Hoelzel, W.,
950 Jorgensen, P.J., Kanno, T., Kessner, A., Klauke, R., Kristiansen, N., Lessinger, J.M., Linsinger, T.P.,
951 Misaki, H., Panteghini, M., Pauwels, J., Schiele, F., Schimmel, H.G., Weidemann, G., Siekmann, L.,
952 International Federation of Clinical Chemistry and Laboratory Medicine, 2002b. IFCC primary
953 reference procedures for the measurement of catalytic activity concentrations of enzymes at 37
954 degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 5. Reference
955 procedure for the measurement of catalytic concentration of aspartate aminotransferase. *Clin.*
956 *Chem. Lab. Med.* 40, 725-733.

957 Shimada, T., Fujii-Kuriyama, Y., 2004. Metabolic activation of polycyclic aromatic hydrocarbons to
958 carcinogens by cytochromes P450 1A1 and 1B1. *Cancer Sci.* 95, 1-6.

959 Shmarakov, I.O., 2015. Retinoid-xenobiotic interactions: the Ying and the Yang. *Hepatobiliary. Surg.*
960 *Nutr.* 4, 243-267.

961 Singh, N.P., Hegde, V.L., Hofseth, L.J., Nagarkatti, M., Nagarkatti, P.S., 2007. Resveratrol (trans-3,5,4'-
962 trihydroxystilbene) ameliorates experimental allergic encephalomyelitis, primarily via induction of
963 apoptosis in T cells involving activation of aryl hydrocarbon receptor and estrogen receptor. *Mol.*
964 *Pharmacol.* 72, 1508-1521.

965 Spink, D.C., Eugster, H.-., Lincoln II, D.W., Schuetz, J.D., Schuetz, E.G., Johnson, J.A., Kaminsky, L.S.,
966 Gierthy, J.F., 1992. 17 β -Estradiol hydroxylation catalyzed by human cytochrome P450 1A1: A
967 comparison of the activities induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those
968 from heterologous expression of the cDNA. *Arch. Biochem. Biophys.* 293, 342-348.

969 Stahl, B.U., Kettrup, A., Rozman, K., 1992. Comparative toxicity of four chlorinated dibenzo-p-dioxins
970 (CDDs) and their mixture - Part I: Acute toxicity and toxic equivalency factors (TEFs). *Arch. Toxicol.* 66,
971 471-477.

972 Thoolen, B., Maronpot, R.R., Harada, T., Nyska, A., Rousseaux, C., Nolte, T., Malarkey, D.E.,
973 Kaufmann, W., Küttler, K., Deschl, U., Nakae, D., Gregson, R., Vinlove, M.P., Brix, A.E., Singh, B.,

974 Belpoggi, F., Ward, J.M., 2010. Proliferative and nonproliferative lesions of the rat and mouse
975 hepatobiliary system. *Toxicol. Pathol.* 38, 5S-81S.

976 Tichopad, A., Kitchen, R., Riedmaier, I., Becker, C., Ståhlberg, A., Kubista, M., 2009. Design and
977 optimization of reverse-transcription quantitative PCR experiments. *Clin. Chem.* 55, 1816-1823.

978 Tomaszewski, K.E., Montgomery, C.A., Melnick, R.L., 1988. Modulation of 2,3,7,8-tetrachlorodibenzo-
979 p-dioxin toxicity in F344 rats by di(2-ethylhexyl)phthalate. *Chem. -Biol. Interact.* 65, 205-222.

980 Travis, C.C., Hattemer-Frey, H.A., 1991. Human exposure to dioxin. *Sci. Total Environ.* 104, 97-127.

981 Trinder, P., 1969. Determination of glucose in blood using glucose oxidase with an alternative oxygen
982 acceptor. *Ann. Clin. Biochem.* 6, 24-28.

983 Tuomisto, J.T., Viluksela, M., Pohjanvirta, R., Tuomisto, J., 2000. Changes in food intake and food
984 selection in rats after 2,3,7,8- tetrachlorodibenzo-p-dioxin (TCDD) exposure. *Pharmacol. Biochem.*
985 *Behav.* 65, 381-387.

986 Ueda, Y., Tsuboi, M., Ota, Y., Makita, M., Aoshima, T., Nakajima, M., Narama, I., 2011. Gastric
987 mucosal changes induced by polyethylene glycol 400 administered by gavage in rats. *J. Toxicol. Sci.*
988 36, 811-815.

989 Unkila, M., Pohjanvirta, R., Macdonald, E., Tuomisto, J.T., Tuomisto, J., 1994. Dose Response and
990 Time Course of Alterations in Tryptophan Metabolism by 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)
991 in the Most TCDD-Susceptible and the Most TCDD-Resistant Rat Strain: Relationship with TCDD
992 Lethality. *Toxicol. Appl. Pharmacol.* 128, 280-292.

993 Van Den Berg, M., Birnbaum, L., Bosveld, A.T.C., Brunström, B., Cook, P., Feeley, M., Giesy, J.P.,
994 Hanberg, A., Hasegawa, R., Kennedy, S.W., Kubiak, T., Larsen, J.C., Van Leeuwen, F.X.R., Liem, A.K.D.,
995 Nolt, C., Peterson, R.E., Poellinger, L., Safe, S., Schrenk, D., Tillitt, D., Tysklind, M., Younes, M., Wærn,
996 F., Zacharewski, T., 1998. Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and
997 wildlife. *Environ. Health Perspect.* 106, 775-792.

998 Van Den Bogaard, E.H., Bergboer, J.G.M., Vonk-Bergers, M., Van Vlijmen-Willems, I.M.J.J., Hato, S.V.,
999 Van Der Valk, P.G.M., Schröder, J.M., Joosten, I., Zeeuwen, P.L.J.M., Schalkwijk, J., 2013. Coal tar
1000 induces AHR-dependent skin barrier repair in atopic dermatitis. *J. Clin. Invest.* 123, 917-927.

1001 van der Ven, L.T.M., van de Kuil, T., Leonards, P.E.G., Slob, W., Lilienthal, H., Litens, S., Herlin, M.,
1002 Håkansson, H., Cantón, R.F., van den Berg, M., Visser, T.J., van Loveren, H., Vos, J.G., Piersma, A.H.,
1003 2009. Endocrine effects of hexabromocyclododecane (HBCD) in a one-generation reproduction study
1004 in Wistar rats. *Toxicol. Lett.* 185, 51-62.

1005 Varrin-Doyer, M., Zamvil, S.S., Schulze-Topphoff, U., 2014. Laquinimod, an up-and-coming
1006 immunomodulatory agent for treatment of multiple sclerosis. *Exp. Neurol.* 262, Part A, 66-71.

1007 Viluksela, M., Raasmaja, A., Lebofsky, M., Stahl, B.U., Rozman, K.K., 2004. Tissue-specific effects of
1008 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on the activity of 5'-deiodinases I and II in rats. *Toxicol.*
1009 *Lett.* 147, 133-142.

1010 Viluksela, M., Unkila, M., Pohjanvirta, R., Tuomisto, J.T., Stahl, B.U., Rozman, K.K., Tuomisto, J., 1999.
1011 Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on liver phosphoenolpyruvate carboxykinase
1012 (PEPCK) activity, glucose homeostasis and plasma amino acid concentrations in the most TCDD-
1013 susceptible and the most TCDD-resistant rat strains. *Arch. Toxicol.* 73, 323-336.

1014 Vos, J.G., Moore, J.A., Zinkl, J.G., 1974. Toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in
1015 C57BL/6 mice. *Toxicol. Appl. Pharmacol.* 29, 229-241.

1016 Wahlefeld, A.W., 1974. Triglycerides. Determination after enzymatic hydrolysis., in: Bergmeyer, H.U.
1017 (Ed.), *Methods of Enzymatic Analysis*, 2nd English ed. Acad. Press, New York; NY; U.S.A., pp. 1831-
1018 1835.

1019 Weinstein, D.A., Gogal Jr., R.M., Mustafa, A., Prater, M.R., Holladay, S.D., 2008. Mid-gestation
1020 exposure of C57BL/6 mice to 2,3,7,8-tetrachlorodibenzo-p-dioxin causes postnatal morphologic
1021 changes in the spleen and liver. *Toxicol. Pathol.* 36, 705-713.

1022 White, S.S., Fenton, S.E., Birnbaum, L.S., 2011. 22. Adverse Health Outcomes Caused By Dioxin-
1023 Activated AHR in Humans, in: Pohjanvirta, R. (Ed.), *The AH Receptor in Biology and Toxicology*. John
1024 Wiley & Sons, Inc., pp. 307-316.

1025 Zhu, C., Xie, Q., Zhao, B., 2014. The role of AhR in autoimmune regulation and its potential as a
1026 therapeutic target against CD4 T cell mediated inflammatory disorder. *Int. J. Mol. Sci.* 15, 10116-
1027 10135.

1028

1029

Tables

Table 1 Expression of AHR-battery genes related to xenobiotic metabolism and *Cyp2b1* in S-D rat liver triggered by C2 (100/mg/kg/day) and C4 (75 mg/kg/day; 5-day dosing regimen followed by 5-day monitoring period before euthanasia) vs. controls. For comparison, data from TCDD-treated^a (100 µg/kg single dose) L-E and H/W rats vs. controls are shown. (+)=Statistically significant induction, (–)=no statistical significance (p<0.05, one-way ANOVA/Student-Newman-Keuls or Student's t-test). Fold change^b in brackets

Gene	C2	C4	TCDD (L-E)	TCDD (H/W)
<i>Cyp1a1</i>	+ (370)	+ (140)	+ (1100)	+ (860)
<i>Cyp1a2</i>	+ (5)	+ (2)	+ (8)	+ (20)
<i>Cyp1b1</i>	+ (5)	– (1)	+ (1600)	+ (500)
<i>Cyp2b1</i>	– (3)	– (1)	+ (5)	– (1)
<i>Ahrr</i>	+ (6)	+ (3)	+ (230)	+ (160)
<i>Nqo1</i>	+ (3)	– (2)	+ (50)	+ (15)
<i>Tiparp</i>	– (1)	– (1)	+ (25)	+ (9)
<i>Ugt1a</i>	+ (1.4)	– (1.2)	+ (7)	+ (6)

n=5-6 in each group.

^aThe data for the TCDD groups are from a previous study (Lindén, et al. 2014), where TCDD-sensitive L-E and TCDD-resistant H/W rats were exposed to a single ig dose of 100 µg/kg TCDD and euthanised at 10 days. The cDNA for these samples had been reverse-transcribed previously, but qPCR was performed with the same primers and in the same conditions as for C2 and C4.

^b Fold change = the ratio between the mean values for exposed and control rats

Table 2 Concentrations of retinoids in liver, kidney and serum samples from the subacute study, in which vehicle, C2 (100 mg/kg/day) or C4 (75 mg/kg/day) was administered on 5 consecutive days

	Control	C2	C4	p-value ^a
Liver	Mean±SD	Mean±SD	Mean±SD	
All- <i>trans</i> -retinoic acid (pmol/g)	11.8±1.8	15.9±1.9	** 14.1±2.6	0.020
13- <i>cis</i> -retinoic acid (pmol/g)	3.76±0.67	7.70±5.11	4.32±0.89	0.080
4-hydroxy-all- <i>trans</i> -retinoic acid (pmol/g)	1.65±0.64	0.52 ^b ±0.25	*** 0.55 ^b ±0.25	*** 0.001
9- <i>cis</i> -4-oxo-13,14-dh-retinoic acid (pmol/g)	58.6±9.3	4.68±2.25	*** 3.86±1.62	*** <0.001
Retinol (nmol/g)	12.7±1.9	15.9±3.8	16.9±3.6	0.094
Retinyl palmitate (μmol/g)	0.74±0.09	0.41±0.11	*** 0.52±0.11	** <0.001
Serum				
All- <i>trans</i> -retinoic acid (pmol/g)	1.02±0.28	1.14±0.34	1.15±0.24	0.687
13- <i>cis</i> -retinoic acid (pmol/g)	1.36±0.30	0.74±0.16	*** 0.50±0.14	*** <0.001
9- <i>cis</i> -4-oxo-13,14-dh-retinoic acid (pmol/g)	3.52±0.84	1.58±0.56	** 2.15±0.75	** 0.003
Retinol (nmol/g)	2.50±0.19	3.21±0.24	*** 3.12±0.15	*** <0.001
Retinyl palmitate (nmol/g)	0.06±0.01	0.03±0.01	*** 0.03±0.01	*** <0.001
Kidney				
All- <i>trans</i> -retinoic acid (pmol/g)	7.88±0.60	9.92±0.94	** 8.41±1.03	0.005
9- <i>cis</i> -4-oxo-13,14-dh-retinoic acid (pmol/g)	1.15±0.44	1.80±1.00	1.45±0.88	0.423
Retinol (nmol/g)	7.01±0.69	9.32±0.75	*** 9.10±0.62	*** <0.001
Retinyl palmitate (nmol/g)	6.08±5.80	14.50±6.12	* 20.02±7.25	** 0.007

For control and C4 groups, n = 6. For liver C2 and kidney C2, n = 5. For serum C2, n = 4.

9-*cis*-4-oxo-13,14-dihydro-retinoic acid (9-*cis*-4-oxo-13,14-dh-RA).

^a Comparison between groups was performed using one-way analysis of variance (ANOVA).

* Group significantly different vs control group according to linear contrast tests, after significant ANOVA.

^b Some concentrations were close to or below the limit of detection, but were regardless calculated to allow statistical analysis.

Figures




Fig. 1 The AHR activator C1 is formed *in vivo* by hydrolysis of the diacetate prodrug C2, but also in small amounts from laquinimod by N-dealkylation. C3 is similarly formed *in vivo* from the prodrug C4 and tasquinimod.




Fig. 2 Chemical structures of TCDD, C2 and C4, and those of the respective deacetylated metabolites C1 and C3 (used in *in vitro* assays)




Fig. 3 Left panel. The effect of C2 and C4 on BW (S-D rats; n=5–6, mean \pm SD) on days 1, 5 and 9 after the beginning of exposures (day 0). C2 (100 mg/kg/day) and C4 (75 mg/kg/day) were administered ig on five consecutive days (days 0–4). The data in columns with different letters differ significantly from one another ($p < 0.05$, one-way ANOVA/Tukey HSD). **Right panel.** Typical pattern of body weight loss in TCDD-induced wasting syndrome for comparison with the changes caused by C2 and C4. These data originate from a previous study (Lindén, et al. 2014), where TCDD-sensitive L-E rats were exposed to a single ig dose of 100 μ g/kg TCDD (no statistical analysis was conducted)




Fig. 4 The expression of *Cyp1a1* induced by C2 (100 mg/kg/day) and C4 (75 mg/kg/day) vs. controls in liver, duodenum, kidney, lung and testis in S-D rats (n=5-6, mean \pm SD). The rats were exposed to the study compounds for 5 consecutive days, and monitored for further 5 days before euthanasia and sample collection. Columns with unidentical letters differ significantly from one another ($p < 0.05$, one-way ANOVA/Student-Newman-Keuls)




Fig. 5 Relative mean (\pm SD) organ weights (percent of BW) of C2 (100 mg/kg/day), C4 (75 mg/kg/day) and control groups in S-D rats ($n=5-6$). Both compounds were administered ig daily on days 0–4, and the rats were euthanised on day 9. The groups with unidentical letters differ significantly from one another ($p<0.05$, one-way ANOVA/Student-Newman-Keuls)




Fig. 6 Typical minimal hepatic EMH reaction with a lobular sinusoidal aggregate of deeply basophilic hematopoietic cells in C2/C4 group rats in the subacute toxicity experiment (left panel), and a corresponding area with no alterations in the control group for comparison (right panel). Central vein in the left lower corner and portal triad in the right upper corner in both pictures.




Fig. 7 Effects of C2 (100 mg/kg/day) and C4 (75 mg/kg/day) on biochemistry variables in S-D rats (n=5-6, mean \pm SD). Both compounds were administered ig daily on days 0–4, and the rats were euthanised on day 9. The groups with unidentical letters differ significantly from one another ($p < 0.05$, one-way ANOVA/Student-Newman-Keuls). FFA=free fatty acids, 3-HB=D-3-hydroxybutyrate, Trigly=triglycerides, TotChol=total cholesterol, ALAT= alanine aminotransferase, ASAT= aspartate aminotransferase




Fig. 8 *In vitro* CYP1A1 activity induced by 1, 5, 10 or 50 nM of C1, C3 or TCDD in the H4IIE hepatoma cell line, measured by a luminescent method. The data are portrayed as fold changes over controls (n=3; mean \pm SD). *= $p < 0.05$, **= $p < 0.01$, ***= $p < 0.001$, Kruskal-Wallis non-parametric ANOVA followed by pairwise comparisons only with controls, therefore the p-values have not been adjusted. Two-way ANOVA showed a significant compound \times concentration interaction term, and at the 3 highest concentrations, TCDD differed significantly from C1 and C3 (see text for further details)

Supplementary material for “Toxicological characterisation of two novel selective aryl hydrocarbon receptor modulators in Sprague-Dawley rats” by Selma Mahiout, Jere Lindén, Javier Esteban Mozo, Ismael Sánchez-Pérez, Satu Sankari, Lars Pettersson, Helen Håkansson and Raimo Pohjanvirta.


Corresponding author: Selma Mahiout, University of Helsinki, selma.mahiout@helsinki.fi

Supplementary Table 1 Primer sequences used in RT-qPCR runs. The primers were designed to span exon-exon junctions to further eliminate amplification of genomic DNA

Target gene	Forward primer-5'	Reverse-primer-3'	Amplicon (bp)	Amplification efficiency
<i>Cyp1a1</i>	gtcaggacaggaggctggac	gattgtgtcaaaccagctc	101	0.89–1.04
<i>Cyp1a2</i>	tcaaccatgatgagaagcagtg	actcagggtctgtcgatgg	95	0.94–0.96
<i>Cyp1b1</i>	gctggatttgaggatgtgc	gcaggtaggctggtaaagagg	111	0.97
<i>Cyp2b1</i>	ttgaccacccagacagcttc	acaaatgcgctttcctgtgg	104	0.98–1
<i>Ahrr</i>	ctggcttcctgactatgcag	cgccacaatgcaaaacaagg	116	0.91–0.97
<i>Nqo1</i>	agggtcctttccagaataagaag	tgaattggccagagaatgacg	115	1
<i>Tiparp</i>	caactctcgggtctgaaag	cccaccaagtgtctgtaaataatgg	148	0.95
<i>Ugt1</i>	aacgatctgcttggtcatcc	gcgttgctcatctgatcacc	131	0.96–0.97

Supplementary Table 2 Body weight (BW) gain (% , mean \pm SD) and relative (% of terminal BW) thymus and liver weights (mean \pm SD) in the acute toxicity study. The rats received a single dose of vehicle, C2 or C4 (3 dose levels), and were euthanised 7–13 days later. BW gain at 7 days after exposure is shown relative to the weight (%) on the day of exposure. Due to a low number of rats in the middle groups , only the highest dosage groups of C2 and C4 were statistically compared with the control (in bold). The groups with non-identical letters differ significantly from one another ($p < 0.05$). Statistical analysis was performed by one-way ANOVA followed by Duncan’s new multiple range test

	Control	C2 (mg/kg)			C4 (mg/kg)		
		8.75	30.0	92.5	8.75	27.5	75.0
	n=6	n=1	n=2	n=3	n=2	n=2	n=3
BW gain (% \pm SD)	11.8 \pm 2.6 a	12.6	12.0 \pm 0.1	7.8 \pm 3.2 ab	11.9 \pm 0.1	7.7 \pm 0.3	6.1 \pm 1.8 b
Thymus (% BW \pm SD)	0.18 \pm 0.02 a	0.12	0.17 \pm 0.01	0.12 \pm 0.01 b	0.16 \pm 0.0	0.15 \pm 0.02	0.13 \pm 0.03 b
Liver (% BW \pm SD)	4.2 \pm 0.51	4.3	4.2 \pm 0.04	3.8 \pm 0.18	4.3 \pm 0.08	3.9 \pm 0.16	3.8 \pm 0.19



Supplementary Fig. 1 Transient hyperaemia of the ear pinnae inflicted by C2 (100 mg/kg/day, 5 day repeated dosing) and C4 (75 mg/kg/day, 5 day repeated dosing), bilateral in the left panel and unilateral (right ear) in the right panel. The effect appeared on the first day after the repeated dosing regimen and persisted for 3-4 days. The pictures here were taken on the 3rd day the effect was observed

Supplementary Table 3 Observed EMH in the spleen across groups (n=5–6) in the subacute toxicity study. The severities of findings were graded on a scale of 1 to 4 as minimal, mild, moderate or marked, respectively. The grades of severity for microscopic findings were subjective; minimal was the least extent discernible

Grade	Controls	C2 (100 mg/kg/day)	C4 (75 mg/kg/day)
None (0)	1/6	–	–
Minimal (1)	1/6	1/5	1/6
Mild (2)	2/6	3/5	2/6
Moderate (3)	2/6	1/5	3/6
Marked (4)	–	–	–

Supplementary Table 4 Thyroxine absorbances (mean \pm SD; n=5–6) in sera collected upon termination of the subacute toxicity test in S-D rats, determined with an ELISA kit. For comparison and verification of the method, as a positive control, sera from TCDD sensitive L-E rats collected at 10 days after exposure to 100 μ g/kg TCDD or the vehicle (Lindén et al. 2014) were run on the same ELISA plate and handled identically to the actual samples. Statistical analysis was performed using Kruskal-Wallis non-parametric ANOVA or Mann-Witney U test

Strain	Control	C2	C4	TCDD	p-value
S-D	0.81 \pm 0.11	0.80 \pm 0.21	0.75 \pm 0.13	–	0.426
L-E	0.99 \pm 0.09	–	–	2.16 \pm 0.13	0.008